Expert Review of Clinical Immunology Expert Review of Clinical Immunology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Durability and long-term outcomes of biologic therapies in psoriasis
Expert Rev Clin Immunol. 2023 Aug 23. doi: 10.1080/1744666X.2023.2250918. Online ahead of print.ABSTRACTINTRODUCTION: Significant advances in psoriasis treatment have taken place since the introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics approved and at that time greatly improved psoriasis treatment. However, newer biologics, directed to interleukin(IL)-23/IL-17 pathways central to psoriasis pathogenesis,have improved complete or nearly complete clearance rates and are characterized by an excellent safety profile.Real-world setting experiences have generally confirmed the result...
Source: Expert Review of Clinical Immunology - August 23, 2023 Category: Allergy & Immunology Authors: Llu ís Rusiñol Elena Carmona-Rocha Llu ís Puig Source Type: research

Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease
Expert Rev Clin Immunol. 2023 Aug 22:1-15. doi: 10.1080/1744666X.2023.2249230. Online ahead of print.ABSTRACTINTRODUCTION: Acute and chronic graft-versus-host disease (GvHD) are potentially life-threatening complications occurring after allogeneic stem cell transplantation (allo-HSCT). Although steroids represent the first-line treatment for both conditions, in those patients who do not adequately benefit from steroid therapy, standardized treatment algorithms are lacking. In recent years, ruxolitinib has emerged as the most promising agent for the second-line therapy of steroid-refractory (SR)-GvHD.AREAS COVERED: This rev...
Source: Expert Review of Clinical Immunology - August 22, 2023 Category: Allergy & Immunology Authors: Mattia Algeri Marco Becilli Franco Locatelli Source Type: research

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Expert Rev Clin Immunol. 2023 Aug 18. doi: 10.1080/1744666X.2023.2249237. Online ahead of print.ABSTRACTINTRODUCTION: Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune, and myeloproliferative disorders. Recently concern has arisen regarding their safety in patients with rheumatoid arthritis.AREAS COVERED: Here we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on comparative safety, and provide insight into their future and use. We emphasize that the application of the research findings on a case-by-case basis s...
Source: Expert Review of Clinical Immunology - August 19, 2023 Category: Allergy & Immunology Authors: Kate Tokareva Pankti Reid Victor Yang David Liew Alexander C Peterson Aaron Baraff Jon Giles Namrata Singh Source Type: research